New York A08576 aims to preserve access to affordable drugs by presuming anticompetitive effects in patent infringement settlements involving.

New York A08576 amends the public health law to address agreements resolving or settling patent infringement claims related to pharmaceutical products. The bill presumes that such agreements have anticompetitive effects if a nonreference drug filer receives anything of value from another company asserting patent infringement and if the nonreference drug filer agrees to limit or forego research, development, manufacturing, marketing, or sales of their product.

New York A08576 aims to preserve access to affordable drugs by presuming anticompetitive effects in patent infringement settlements involving.

New York A08576 amends the public health law to address agreements resolving or settling patent infringement claims related to pharmaceutical products. The bill presumes that such agreements have anticompetitive effects if a nonreference drug filer receives anything of value from another company asserting patent infringement and if the nonreference drug filer agrees to limit or forego research, development, manufacturing, marketing, or sales of their product.